Clinical Trials List
2006-11-20 - 2015-12-31
Phase III
Terminated11
ICD-10C79.81
Secondary malignant neoplasm of breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9198.81
Secondary malignant neoplasm of breast
-
Trial Applicant
台灣法瑪特股份有限公司
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 林璟宏 Division of Hematology & Oncology
- YEN-SHEN LU Division of Hematology & Oncology
- SUNG-HSIN KUO Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Fu Ouyang Division of Gastroenterological Surgery
- Fang-Ming Chen Division of Gastroenterological Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Kuo-Ting Lee Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Yung-Chang Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 劉建良 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 楊陽生 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 高偉堯 Division of Hematology & Oncology
- Tsu-Yi Chao Division of Hematology & Oncology
- 俞志誠 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 林明賢 Division of Hematology & Oncology
- Shang-Hung Chen Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 陳威宇 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 劉建良 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
0 participants
-
Global
0 participants
